We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+6.99%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$184M
AUM Growth
+$42.5M
(+30%)
Cap. Flow
+$36.1M
Cap. Flow
% of AUM
19.61%
Top 10 Holdings %
Top 10 Hldgs %
31.33%
Holding
99
New
45
Increased
12
Reduced
8
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$5.07M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$4.94M |
| 3 |
CYBX
CYBERONICS INC
CYBX
|
+$4.32M |
| 4 |
AGN
Allergan Inc
AGN
|
+$4.15M |
| 5 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$4.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$6.17M |
| 2 |
Cooper Companies
COO
|
+$5.42M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$5.24M |
| 4 |
Boston Scientific
BSX
|
+$5.11M |
| 5 |
Insmed
INSM
|
+$4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.11% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
Neurocrine Biosciences
NBIX
$17.2B
| $3.13M | 1.7% |
+200,000
| New | +$2.99M |
|
|
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.95M | 1.6% |
+65,000
| New | +$2.72M |
|
|
PTLA
28
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.91M | 1.58% |
+115,000
| New | +$3.03M |
|
|
GWPH
29
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $2.83M | 1.54% |
35,000
+15,000
| +75% | +$1.33M |
|
30
Alnylam Pharmaceuticals
ALNY
$35.7B
| $2.73M | 1.48% |
35,000
-40,000
| -53% | -$2.58M |
|
31
QuidelOrtho
QDEL
$1.19B
| $2.69M | 1.46% |
+100,000
| New | +$2.39M |
|
|
SPNC
32
DELISTED
Spectranetics Corp
SPNC
| $2.66M | 1.44% |
100,000
-42,600
| -30% | -$1.14M |
|
33
Bruker
BRKR
$8.86B
| $2.59M | 1.41% |
140,000
+10,000
| +8% | +$214K |
|
34
Edwards Lifesciences
EW
$49.4B
| $2.55M | 1.39% |
150,000
+30,000
| +25% | +$474K |
|
|
EXAS
35
DELISTED
Exact Sciences
EXAS
| $2.42M | 1.32% |
+125,000
| New | +$2.29M |
|
|
CMRX
36
DELISTED
Chimerix, Inc.
CMRX
| $2.22M | 1.21% |
+80,500
| New | +$1.95M |
|
37
PTC Therapeutics
PTCT
$6.52B
| $2.2M | 1.19% |
+50,000
| New | +$1.56M |
|
|
ATRS
38
DELISTED
Antares Pharma, Inc.
ATRS
| $2.01M | 1.09% |
+1,100,000
| New | +$2.4M |
|
|
AEGR
39
DELISTED
Aegerion Pharmaceuticals
AEGR
| $2M | 1.09% |
+60,000
| New | +$1.86M |
|
40
Medtronic
MDT
$106B
| $1.86M | 1.01% |
30,000
-45,000
| -60% | -$2.86M |
|
|
ASRT
41
DELISTED
Assertio
ASRT
| $1.82M | 0.99% |
2,000
| – | – |
|
42
Tandem Diabetes Care
TNDM
$1.17B
| $1.76M | 0.96% |
+13,150
| New | +$1.84M |
|
|
NUVA
43
DELISTED
NuVasive, Inc.
NUVA
| $1.74M | 0.95% |
+50,000
| New | +$1.78M |
|
|
ADVM
44
DELISTED
Adverum Biotechnologies
ADVM
| $1.71M | 0.93% |
+5,000
| New | +$1.49M |
|
|
45
Neurocrine Biosciences
NBIX
$17.2B
| $1.57M | 0.85% |
+100,000
| New | +$1.49M |
|
|
ACHN
46
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.5M | 0.81% |
150,000
| – | – |
|
47
Larimar Therapeutics
LRMR
$384M
| $1.47M | 0.8% |
+6,250
| New | +$1.42M |
|
48
Enanta Pharmaceuticals
ENTA
$400M
| $1.39M | 0.75% |
35,000
-15,000
| -30% | -$598K |
|
|
CASC
49
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $1.34M | 0.73% |
+116,667
| New | +$1.78M |
|
50
Smith & Nephew
SNN
$12.9B
| $1.26M | 0.69% |
37,500
-12,500
| -25% | -$436K |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2014 Portfolio in Review
As of Q3 2014, Ghost Tree Capital held 99 positions worth $184M, up 30% from $142M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ghost Tree Capital deployed $36.1M of net new capital in Q3 2014, opening 45 new positions and adding to 12 existing holdings. Its largest new stake was Zimmer Biomet: 51,500 shares worth $5.03M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 60% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Allergan plc, an estimated $3.36M trimmed.
- Ghost Tree Capital's largest Q3 2014 buy was Zimmer Biomet: 51,500 shares worth $5.03M.
- Ghost Tree Capital added most to TherapeuticsMD in Q3 2014, an estimated $2.52M increase.
- Ghost Tree Capital's biggest Q3 2014 reduction was Allergan plc, cutting an estimated $3.36M.
- Ghost Tree Capital fully exited MEDIVATION, INC. in Q3 2014, selling an estimated $6.17M.
- Ghost Tree Capital's ten largest holdings make up 31% of its $184M portfolio in Q3 2014.
- Ghost Tree Capital opened 45 new positions and closed 29 in Q3 2014.
- Ghost Tree Capital's portfolio value rose 30% quarter-over-quarter to $184M.
Based on Ghost Tree Capital's 13F filing for Q3 2014, filed 14 Nov 2014.